168 related articles for article (PubMed ID: 38451522)
1. Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict Prostate Cancer Risk.
Patel HD; Remmers S; Ellis JL; Li EV; Roobol MJ; Fang AM; Davik P; Rais-Bahrami S; Murphy AB; Ross AE; Gupta GN
JAMA Netw Open; 2024 Mar; 7(3):e241516. PubMed ID: 38451522
[TBL] [Abstract][Full Text] [Related]
2. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
Patel HD; Koehne EL; Shea SM; Fang AM; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
[TBL] [Abstract][Full Text] [Related]
3. Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres.
Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H
BJU Int; 2024 Mar; 133(3):278-288. PubMed ID: 37607322
[TBL] [Abstract][Full Text] [Related]
4. Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer.
Rius Bilbao L; Aguirre Larracoechea U; Valladares Gomez C; Remmers S; Mar Medina C;
World J Urol; 2024 Mar; 42(1):141. PubMed ID: 38478041
[TBL] [Abstract][Full Text] [Related]
5. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
6. A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
Doan P; Graham P; Lahoud J; Remmers S; Roobol MJ; Kim L; Patel MI
BJU Int; 2021 Dec; 128 Suppl 3():36-44. PubMed ID: 34374190
[TBL] [Abstract][Full Text] [Related]
7. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
8. Rotterdam mobile phone app including MRI data for the prediction of prostate cancer: A multicenter external validation.
De Nunzio C; Lombardo R; Baldassarri V; Cindolo L; Bertolo R; Minervini A; Sessa F; Muto G; Bove P; Vittori M; Bozzini G; Castellan P; Mugavero F; Falsaperla M; Schips L; Celia A; Bada M; Porreca A; Pastore A; Al Salhi Y; Giampaoli M; Novella G; Rizzetto R; Trabacchin N; Mantica G; Pini G; Remmers S; Antonelli A; Tubaro A
Eur J Surg Oncol; 2021 Oct; 47(10):2640-2645. PubMed ID: 33965292
[TBL] [Abstract][Full Text] [Related]
9. External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
Palsdottir T; Grönberg H; Hilmisson A; Eklund M; Nordström T; Vigneswaran HT
Eur Urol Focus; 2023 May; 9(3):455-462. PubMed ID: 36522257
[TBL] [Abstract][Full Text] [Related]
10. Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
Deniffel D; Healy GM; Dong X; Ghai S; Salinas-Miranda E; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Perlis N; Haider MA
Radiology; 2021 Aug; 300(2):369-379. PubMed ID: 34032510
[TBL] [Abstract][Full Text] [Related]
11. External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort.
Chandra Engel J; Palsdottir T; Ankerst D; Remmers S; Mortezavi A; Chellappa V; Egevad L; Grönberg H; Eklund M; Nordström T
Eur Urol Open Sci; 2022 Jul; 41():1-7. PubMed ID: 35813248
[TBL] [Abstract][Full Text] [Related]
12. External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer.
Saba K; Wettstein MS; Lieger L; Hötker AM; Donati OF; Moch H; Ankerst DP; Poyet C; Sulser T; Eberli D; Mortezavi A
J Urol; 2020 Apr; 203(4):719-726. PubMed ID: 31651228
[TBL] [Abstract][Full Text] [Related]
13. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
14. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
15. External validation of two MRI-based risk calculators in prostate cancer diagnosis.
Petersmann AL; Remmers S; Klein T; Manava P; Huettenbrink C; Pahernik SA; Distler FA
World J Urol; 2021 Nov; 39(11):4109-4116. PubMed ID: 34169337
[TBL] [Abstract][Full Text] [Related]
16. Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data.
Remmers S; Kasivisvanathan V; Verbeek JFM; Moore CM; Roobol MJ;
Eur Urol Open Sci; 2022 Feb; 36():1-8. PubMed ID: 35098168
[TBL] [Abstract][Full Text] [Related]
17. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy.
Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D
Eur Urol Open Sci; 2023 Jul; 53():90-97. PubMed ID: 37441340
[TBL] [Abstract][Full Text] [Related]
18. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
[TBL] [Abstract][Full Text] [Related]
19. External validation and comparison of magnetic resonance imaging-based predictive models for clinically significant prostate cancer.
Lee HJ; Lee A; Yang XY; Law YM; Huang HH; Lau WK; Lee LS; Ho HS; Cheng CW; Yuen JS; Tay KJ; Chen K
Urol Oncol; 2021 Nov; 39(11):783.e1-783.e10. PubMed ID: 33775528
[TBL] [Abstract][Full Text] [Related]
20. Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study.
Chen IA; Chu CH; Lin JT; Tsai JY; Yu CC; Sridhar AN; Sooriakumaran P; Loureiro RCV; Chand M
J Med Internet Res; 2020 Dec; 22(12):e16322. PubMed ID: 33337340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
